| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C22orf9 |
| Uniprot No | Q6ICG6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-404aa |
| 氨基酸序列 | MLRAIAEERGRLSLRREVCGLGCFKDDRIVFWTWMFSTYFMEKWAPRQDDMLFYVRRKLAYSGSESGADGRKAAEPEVEVEVYRRDSKKLPGLGDPDIDWEESVCLNLILQKLDYMVTCAVCTRADGGDIHIHKKKSQQVFASPSKHPMDSKGEESKISYPNIFFMIDSFEEVFSDMTVGEGEMVCVELVASDKTNTFQGVIFQGSIRYEALKKVYDNRVSVAARMAQKMSFGFYKYSNMEFVRMKGPQGKGHAEMAVSRVSTGDTSPCGTEEDSSPASPMHERVTSFSTPPTPERNNRPAFFSPSLKRKVPRNRIAEMKKSHSANDSEEFFREDDGGADLHNATNLRSRSLSGTGRSLVGSWLKLNRADGNFLLYAHLTYVTLPLHRILTDILEVRQKPILMT |
| 分子量 | 72.2 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人C22orf9蛋白的示例性参考文献列表（注：C22orf9研究较少，部分内容基于假设性文献，建议通过数据库核实）：
1. **文献名称**: *"Functional characterization of the C22orf9 protein in mitochondrial metabolism"*
**作者**: Smith A, et al.
**摘要**: 研究揭示C22orf9定位于线粒体，可能参与调节脂肪酸氧化通路，重组蛋白体外实验显示其与电子传递链复合物存在相互作用。
2. **文献名称**: *"Expression and purification of recombinant human C22orf9 for structural analysis"*
**作者**: Zhang L, et al.
**摘要**: 描述了大肠杆菌系统中重组C22orf9蛋白的优化表达与纯化流程，并通过质谱和圆二色光谱验证其结构稳定性。
3. **文献名称**: *"C22orf9 genetic variants and association with neurodegenerative disorders"*
**作者**: García-Ruiz C, et al.
**摘要**: 发现C22orf9基因多态性与早发性阿尔茨海默病存在相关性，重组蛋白的细胞实验表明其可能通过调控氧化应激通路影响神经元存活。
4. **文献名称**: *"Bioinformatic and functional analysis of the uncharacterized protein C22orf9"*
**作者**: Tanaka K, et al.
**摘要**: 通过同源建模预测C22orf9具有水解酶结构域，重组蛋白的酶活实验证实其对特定脂类底物具有催化活性。
**注意**：C22orf9相关研究较有限，上述内容为模拟文献框架。实际文献需通过PubMed、Google Scholar等平台以"Chromosome 22 open reading frame 9"或最新命名检索。
The human C22orf9 protein, also known as HSPC103 or HT029, is encoded by the C22orf9 gene located on chromosome 22q13.1. First identified through genomic sequencing efforts, this evolutionarily conserved protein remains poorly characterized compared to many other human proteins. Structural analyses predict it to be a transmembrane protein containing 170-180 amino acids, with potential N-terminal signal peptides suggesting involvement in secretory pathways or membrane trafficking. Limited functional studies indicate its possible roles in cellular adhesion, cell cycle regulation, and apoptosis modulation. Interestingly, C22orf9 shows elevated expression in specific tissues like testis and liver. Emerging research links it to cancer progression, particularly in hepatocellular carcinoma and gliomas, where abnormal expression correlates with tumor aggressiveness. As a recombinant protein, C22orf9 is produced via molecular cloning for biochemical studies, enabling exploration of its interaction networks and post-translational modifications. Despite lacking a definitive functional classification, its conservation across eukaryotes and association with critical cellular processes highlight potential biological significance. Current challenges include resolving its precise molecular mechanisms and validating proposed interactions with signaling pathways like Wnt/β-catenin. Further investigation using gene-editing and proteomic approaches may clarify its therapeutic potential in associated diseases.
×
